Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…Abstract Number: 0627 • ACR Convergence 2021
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…Abstract Number: 0657 • ACR Convergence 2021
Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult healthcare can be a challenging task, with high morbidity and mortality. In response, we have…Abstract Number: 037 • 2020 Pediatric Rheumatology Symposium
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…Abstract Number: 039 • 2020 Pediatric Rheumatology Symposium
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Background/Purpose: Patients with childhood-onset rheumatologic diseases live well into adulthood and need effective transition from pediatric to adult medical providers. Fortunately, predictors of successful transition…Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…Abstract Number: 173 • 2020 Pediatric Rheumatology Symposium
Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement
Background/Purpose: Henoch-Schönlein Purpura (HScP) is the most common form of vasculitis in children, with gastrointestinal (GI) complaints occurring in more than a third of patients…Abstract Number: 174 • 2020 Pediatric Rheumatology Symposium
Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients
Background/Purpose: Communication, including clear discharge instructions, is a crucial aspect of the hospital discharge process. Development of standardized discharge templates has been reported to improve…Abstract Number: 190 • 2020 Pediatric Rheumatology Symposium
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Background/Purpose: Rapid identification of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) coupled with a multidisciplinary approach to management is essential to improve patient outcomes.…Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…
- 1
- 2
- 3
- …
- 5
- Next Page »